Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In an era of increased focus on precision medicine, tumour-agnostic therapies have emerged as a revolutionary new approach to cancer treatment. Tumour-agnostic therapies target specific genomic anomalies or molecular features regardless of tumour site of origin. Pan-tumour approaches signal an important new paradigm in clinical management, whereby tumour genomic signature supersedes histology in informing treatment decisions. In recent years, tumour-agnostic therapies have become a key focus area for an increasing number of small and large pharmaceutical companies.
